A B S T R A C T Extractable nuclear antigen (ENA) is composed of at least two components, one a ribonucleoprotein sensitive to ribonuclease or heat and the other a protein. Antibodies to ENA are associated with a relatively benign clinical course in patients with systemic lupus erythematosus (SLE) in which DNA anti-DNA complexes are thought pathogenic. The effect of ENA and anti-ENA on DNA anti-DNA reactions in vitro was studied. ENA effectively inhibited an anti-DNA hemagglutination reaction but no effect was found on binding of radioactive DNA or on the antihemocyanin hemagglutination reaction. The inhibitory effect was not abolished by yeast ribonuclease (RNase), heating, or DNase. Anti-ENA had no effect on anti-DNA hemagglutination. In vivo, ENA altered the NZB/NZW mouse nephritis thought to be a model for human SLE nephritis. These results suggest the possibility of a role for ENA in alteration of diseases due to pathogenic DNA anti-DNA complexes.
INTRODUCTION
Patients with SLE appear to respond better to corticosteroids and have a more benign course with less severe renal disease if their sera contain antibodies to ENA (4) . Patients with the MCTD syndrome, who manifest features of scleroderma, polymyositis, and SLE but rarely have renal disease, have high titers of hemagglutinating antibodies against ENA (2) . These clinical observations suggest a possible protective role of ENA or antibodies to ENA.
Female NZB/NZW hybrid mice consistently develop several autoimmune phenomena and a lethal nephritis thought due in part to DNA anti-DNA complexes (5) . Their disease is felt by many investigators to be an animal model analogous to human SLE.
We are studying the possible biologic roles of ENA and of antibodies to ENA. In the present studies we have investigated possible inhibitory activity by ENA and antibodies to ENA in DNA anti-DNA reactions in vitro. The possibility of in vivo activity of ENA has been explored using the NZB/NZW mouse nephritis model.
METHODS
ENA was prepared from fresh calf thymus nuclei as previously described (2) , and stored at -70'C. As with S /Amol/ml MgCI2 added for DNase only. RNase solution was heat-treated for 5 min at 80'C to eliminate DNase activity. Where indicated, DNase was inactivated after the 1 h incubation by addition of 0.1 ml of 0.01 M sodium citrate. For both enzymes, pH during incubation was 6.83. "Heated" ENA was added after incubation in solution at 56°C for 2 h. Anti-ENA serum containing antibodies to RNP or Sm was added undiluted or in 1: 5 dilution.
Quantitative DNA assay was done by the diphenylamine method (6) . DNase activity was assayed by degradation of tritiated thymidine-labeled DNA into acid-soluble mononucleotides or oligonucleotides (7) .
DNA binding by human sera was measured by a modification (see Table II ) of the method previously described (8) . ENA was added as 20 ,uI of 50, 10, 1.0, or 0.01 mg/ml concentration of ENA in tris buffer either before or after the usual incubation for 1 h at 37'C. Binding of native DNA by mouse sera was tested in a similar manner except 'Obtained from Worthington Biochemical Corp., Freehold, N. J. that labeled DNA was derived from cultured L1210 mouse leukemia cells.
To explore the in vivo effect of ENA, NZB/NZW hybrid mice were bred from stock colonies maintained by the Department of Laboratory Animal Medicine at the University of Missouri. 52 females were randomized into treatment and control groups at approximately 3i mo of age from within individual litters. Treated animals were given weekly intraperitoneal injections of 1 mg ENA in 0.25 ml saline and controls received only saline. All mice were bled retroorbitally before the study, at monthly intervals, and terminally for determination of DNA-binding activity. Animals were sacrificed at 230, 250, or 270 days. Kidneys were examined by light microscopy after staining with hematoxylin and eosin or periodic acid Schiff and the disease quantitated by grading 40-60 individual glomeruli from 0 (no disease) to 4 on the basis of increasing cellularity and the appearance of neutrophils, necrosis, and sclerosis. Animals who had an average score of 0-2 were considered to have mild disease and those with averages of 3-4 as having severe disease. Direct immunofluorescence for glomerular gamma globulin was carried out by a modification of the method of Allansmith (9) . Tissue was quick frozen in isopentane and liquid nitrogen, lyophilized, and embedded in paraffin. Percentages of diffuse and of focal glomerular staining were recorded from duplicate coded slides.
RESULTS
To determine whether antibodies to ENA could inhibit native DNA anti-DNA hemagglutination, three sera of known high titer hemagglutinating activity against RNP and two with activity against the Sm antigen were tested by addition to the DNA anti-DNA hemagglutination system (see Table I ). Sera were added as 0.1-ml solutions in NRS varying from undiluted to 1: 50 dilution. In no case was the hemagglutinating titer of anti-DNA reduced by the addition of anti-ENA.
The effect of ENA on the radioactive DNA-binding assay for antinative DNA was studied as outlined in Table II . Sera of several different patients gave similar results. As shown, ENA caused no significant change in binding activity. If ENA was added after the incubation which is a normal part of our binding procedure, results were the same as those shown in Table II . Reagents were added in order listed. Volumes in tubes were kept equal by addition of appropriate amounts of buffer.
* ENA incubated for 2 h at 560C.
The effect of ENA on the hemagglutination reaction of antinative DNA was studied by the addition of 1 mg of ENA to each serial dilution of the anti-DNA serum. Table III (lines a-c) presents our finding that ENA clearly inhibits the reaction. Earlier studies had shown that the use of smaller amounts of ENA produced a significant but smaller reduction in titer.
Because of the theoretic possibility that trace contaminants of DNA might inhibit the anti-DNA hemagglutination reaction, we tested the effect of pretreating the ENA with DNase. The results of that procedure and appropriate controls are presented in lines d through g of Table III . DNase failed to prevent inhibition of anti-DNA by ENA when the DNase was subsequently Since the RNP component of ENA loses its antigenic activity when exposed to RNase or heat, we studied the effects of these treatments on the ENA used to inhibit the anti-DNA hemagglutination reaction as seen in Table III (lines h-j). No significant loss of inhibitory activity occurred with either RNase or heat treatment of the ENA. RNase alone did not reduce the titer.
To explore the effect of ENA on a completed DNA anti-DNA reaction, a DNA anti-DNA hemagglutination reaction set up in duplicate was allowed to proceed to completion. After withdrawing 0.25 ml of fluid from each tube, 0.25 ml of NRS containing 1 mg ENA was added to one row of tubes and 0.25 ml of NRS without ENA was added to the other row. The agglutinated cells were resuspended and allowed to settle. Tubes without ENA showed the previous agglutination pattern whereas the cells in the tubes to which ENA was added settled as buttons, indicating a negative reaction. To show that the effect of ENA was not a nonspecific effect on the hemagglutination reaction, 1 mg of ENA was added to each dilution in a rabbit antihemocyanin hemagglutination test. There was no change in the 1:1,280 titer of this reaction. The fact that ENA has no influence on the hemagglutination reaction against hemocyanin makes it unlikely that a nonspecific effect on the hemagglutination reaction itself is involved and it also seems unlikely, in view of the sequence of events in our test and the observations by Hamburger et al. (13) that ENA significantly interferes with adherence of DNA to the tanned cells.
Our data suggest that it is an RNase and heat-insensitive material which interferes with the DNA anti-DNA reaction. It is, therefore, a reasonable possibility that the interference is mediated by Sm antigen, but it could also be due to a currently unidentified component of ENA or an RNase and heat-resistant part of the RNP portion of ENA. It has been suggested (2) that antibodies to ENA could themselves exert a protective effect in patients with SLE or MCTD. Our finding that anti-ENA has no effect in vitro fails to support this possibility.
The 
